Kurzfassung der KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (Leitlinie für die klinische Praxis zur Diabetesbehandlung bei chronischer Nierenkrankheit): eine Aktualisierung auf Grundlage neuer Erkenntnisse

Zusammenfassung

Die Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Klinische Praxisrichtlinie für die Behandlung des Diabetes bei chronischer Nierenkrankheit (chronic kidney disease, CKD) stellt eine Aktualisierung der KDIGO-Leitlinie 2020 dar. Die Leitlinie richtet sich an eine breite Zielgruppe von Klinikern, die Menschen mit Diabetes und CKD behandeln. Zu den Themenbereichen, deren Empfehlungen auf der Grundlage neuer Erkenntnisse aktualisiert wurden, gehören die Kapitel 1: Umfassende Versorgung von Patienten mit Diabetes und CKD sowie Kapitel 4: Glukosesenkende Therapien bei Patienten mit Typ-2-Diabetes (T2 D) und CKD. Der Inhalt früherer Kapitel zur glykämischen Überwachung und zu den Zielen bei Patienten mit Diabetes und CKD (Kapitel 2), Lebensstilinterventionen bei Patienten mit Diabetes und CKD (Kapitel 3) und Ansätzen für das Management von Patienten mit Diabetes und CKD (Kapitel 5) werden als aktuell erachtet und wurden nicht geändert. Diese aktualisierte Leitlinie wurde nach einem eindeutigen Prozess der Evidenzprüfung und -bewertung entwickelt. Die Behandlungsansätze und Leitlinienempfehlungen basieren auf systematischen Übersichten relevanter Studien und Bewertung der Evidenz-Qualität. Die Stärke der Empfehlungen folgt dem GRADE-Ansatz (Grading of Recommendations Assessment, Development and Evaluation).

Die Grenzen der Evidenzen werden erörtert, und es werden Bereiche identifiziert, in denen zusätzliche Forschung erforderlich ist.

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for the Management of Diabetes in Chronic Kidney Disease (CKD) is an update of the KDIGO 2020 guideline. The guideline is aimed at a broad audience of clinicians treating people with diabetes and CKD. Topics with recommendations updated based on new evidence include Chapter 1: Comprehensive Care in Patients with Diabetes and CKD, and Chapter 4: Glucose-Lowering Therapies in Patients with Type 2 Diabetes (T2 D) and CKD. The content of previous chapters on glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), lifestyle interventions in patients with diabetes and CKD (Chapter 3), and approaches to the management of patients with diabetes and CKD (Chapter 5) are considered current and have not been changed. This updated guideline was developed through a rigorous process of evidence review and evaluation. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies and assessment of evidence quality. The strength of the recommendations follows the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation). The limitations of the evidence are discussed, and areas where additional research is needed are identified.

Schlüsselwörter

Angiotensin-Converting-Enzym-Inhibitor - Angiotensin-II-Rezeptor-Blocker - chronische Nierenkrankheit - Dialyse - Evidenzbasiert - GLP-1-Rezeptor-Agonist - Glykämie - glykämische Überwachung - glykämische Ziele - Leitlinie - HbA1c - Hämodialyse - KDIGO - Lebensstil - Metformin - Mineralokortikoid-Rezeptor-Antagonist - Versorgungsmodelle - Ernährung - Renin-Angiotensin-System - Selbstmanagement - SGLT2-Hemmer - systematische Überprüfung - teambasierte Versorgung

Keywords

Angiotensin-converting enzyme inhibitor - Angiotensin II receptor blocker - chronic kidney disease - dialysis - evidence-based - GLP-1 receptor agonist - Glycemia - glycemic monitoring - glycemic targets - guideline - HbA1c (hemoglobin A1c) - hemodialysis - KDIGO (Kidney Disease: Improving Global Outcomes) - lifestyle - metformin - mineralocorticoid receptor antagonist - care models - nutrition - renin-angiotensin system - self-management - SGLT2 inhibitor - systematic review - team-based care

^* Zahlungen an die Institution.

Publikationsverlauf

Artikel online veröffentlicht:
27. Januar 2025

• Literatur

• 1 Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98: S1-S115
• 2 Guyatt GH, Oxman AD, Schunemann HJ. et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-382
• 3 Chan JC, So WY, Yeung CY. et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care 2009; 32: 977-982
• 4 Chan JCN, Thewjitcharoen Y, Nguyen TK. et al. Effect of a web-based management guide on risk factors in patients with type 2 diabetes and diabetic kidney disease: a JADE randomized clinical trial. JAMA Netw Open 2022; 5: e223862
• 5 Gaede P, Vedel P, Parving HH. et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622
• 6 Ueki K, Sasako T, Okazaki Y. et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 951-964
• 7 de Boer IH, Khunti K, Sadusky T. et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022;
• 8 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-1461
• 9 Bhatt DL, Szarek M, Pitt B. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021; 384: 129-139
• 10 Bhatt DL, Szarek M, Steg PG. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021; 384: 117-128
• 11 Cannon CP, Pratley R, Dagogo-Jack S. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383: 1425-1435
• 12 Heerspink HJL, Stefansson BV, Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436-1446
• 13 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008
• 14 Packer M, Anker SD, Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413-1424
• 15 EMPA-Kidney Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 2022; 37: 1317-1329
• 16 Bakris G, Oshima M, Mahaffey KW. et al. Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol 2020; 15: 1705-1714
• 17 Chertow GM, Vart P, Jongs N. et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol 2021; 32: 2352-2361
• 18 Persson F, Rossing P, Vart P. et al. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. Diabetes Care 2021; 44: 1894-1897
• 19 Zoungas S, de Boer IH. SGLT2 inhibitors in diabetic kidney disease. Clin J Am Soc Nephrol 2021; 16: 631-633
• 20 Gerstein HC, Sattar N, Rosenstock J. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021; 385: 896-907
• 21 Alicic RZ, Patakoti R, Tuttle KR. Direct and indirect effects of obesity on the kidney. Adv Chronic Kidney Dis 2013; 20: 121-127
• 22 Bays H, Pi-Sunyer X, Hemmingsson JU. et al. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin 2017; 33: 225-229
• 23 Shah PP, Brady TM, Meyers KEC. et al. Association of obesity with cardiovascular risk factors and kidney disease outcomes in primary proteinuric glomerulopathies. Nephron 2021; 145: 245-255
• 24 Tuttle KR, Lakshmanan MC, Rayner B. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6: 605-617
• 25 Bakris GL, Agarwal R, Anker SD. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383: 2219-2229
• 26 Pitt B, Filippatos G, Agarwal R. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385: 2252-2263
• 27 Rossing P, Anker SD, Filippatos G. FIDELIO-DKD and FIGARO-DKD Investigators. et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY Analysis. Diabetes Care 2022;
• 28 Ito S, Kashihara N, Shikata K. et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol 2020; 15: 1715-1727
• 29 Ito S, Shikata K, Nangaku M. et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase ii trial. Clin J Am Soc Nephrol 2019; 14: 1161-1172
• 30 Neuen BL, Oshima M, Agarwal R. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 2022; 145: 1460-1470
• 31 Neuen BL, Oshima M, Perkovic V. et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J 2021; 42: 4891-4901
• 32 Pitt B, Pfeffer MA, Assmann SF. et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392
• 33 Pitt B, Zannad F, Remme WJ. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
• 34 American Diabetes Association Professional Practice Committee. Draznin B, Aroda VR. et al. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2022. Diabetes Care 2022; 45 (Suppl. 01) S144-S174
• 35 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200
• 36 Yancy CW, Jessup M, Bozkurt B. et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137-e161
• 37 Kliger AS, Brosius FC. Diabetic Kidney Disease Task Force of the American Society of Nephrology. Preserving kidney function instead of replacing it. Clin J Am Soc Nephrol 2020; 15: 129-131
• 38 Chan JCN, Lim LL, Wareham NJ. et al. The Lancet Commission on Diabetes: using data to transform diabetes care and patient lives. Lancet 2021; 396: 2019-2082
• 39 Brosius FC, Cherney D, Gee PO. et al. Transforming the care of patients with diabetic kidney disease. Clin J Am Soc Nephrol 2021; 16: 1590-1600
• 40 Tuttle KR, Wong L, Peter W. et al. Diabetic Kidney Disease Collaborative Task Force. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. disease. Clin J Am Soc Nephrol 2022; 17: 1092-1103
• 41 Abegaz TM, Diaby V, Sherbeny F. et al. Cost effectiveness of dapagliflozin added to standard of care for the management of diabetic nephropathy in the USA. Clin Drug Investig 2022; 42: 501-511
• 42 Igarashi A, Maruyama-Sakurai K, Kubota A. et al. Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan. Diabetes Ther 2022; 13: 1367-1381
• 43 Reifsnider OS, Kansal AR, Wanner C. et al. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial. Am J Kidney Dis 2022; 79: 796-806
• 44 Kelsey MD, Nelson AJ, Green JB. et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison. J Am Coll Cardiol 2022; 79: 1849-1